To develop a suitable and effective vaccine against Staphylococcus aureus (S. aureus), we selected the Hla-MntC-SACOL0723 (HMS) recombinant protein with two different formulations of alum and Monophosphoryl lipid A (MPL) adjuvants. In this study, we aimed to evaluate the potentials of alum and MPL adjuvants in stimulating the immune response of HMS vaccine candidate against S. aureus. To evaluate the type of induced immune response, anti-HMS total IgG, IgG1, IgG2a, and IFN-γ, IL-2, IL-4, and IL-17 cytokines were determined after vaccination of mice with HMS-alum, HMS-MPL candidates. Mice were challenged with Methicillin-resistant Staphylococcus aureus (MRSA) was isolated from pressure sores and evaluated for bacterial load in the kidney homogenates and survival rate. It was observed that total IgG and isotypes (IgG1 and IgG2a), IL-4, and IL-17 were significantly increased in the group that received HMS-alum vaccine compared with the group that received HMS-MPL formulation. On the other hand, the levels of IFN-γ and IL-2 cytokines in the group that received HMS-MPL were higher than the group that received HMS-alum formulation. Bacterial load in the mice who received HMS protein formulated with alum adjuvant was reduced more than the mice who received HMS protein formulated with MPL adjuvant. Histopathological analysis showed more pathological changes in kidney tissues of the group received of HMS-MPL compared with the HMS-alum formulation. The survival rate was equal in both groups of immunized with HMS-alum and HMS-MPL formulations. Finally, it could be concluded that both adjuvants of alum and MPL are suitable immune response enhancers to HMS vaccine candidate.

为了开发一种针对金黄色葡萄球菌( S. aureus )的合适且有效的疫苗，我们选择了 Hla-MntC-SACOL0723 (HMS) 重组蛋白和两种不同配方的明矾和单磷酰脂质 A (MPL) 佐剂。在这项研究中，我们旨在评估明矾和 MPL 佐剂在刺激 HMS 候选疫苗针对金黄色葡萄球菌的免疫反应方面的潜力。为了评估诱导的免疫反应的类型，在用 HMS-alum、HMS- MPL 候选人。用耐甲氧西林金黄色葡萄球菌攻击小鼠(MRSA) 从压疮中分离出来，并评估肾脏匀浆中的细菌负荷和存活率。观察到，与接受 HMS-MPL 制剂的组相比，接受 HMS-明矾疫苗的组的总 IgG 和同种型（IgG1 和 IgG2a）、IL-4 和 IL-17 显着增加。另一方面，接受HMS-MPL的组中IFN-γ和IL-2细胞因子的水平高于接受HMS-明矾制剂的组。接受用明矾佐剂配制的 HMS 蛋白的小鼠的细菌负荷比接受用 MPL 佐剂配制的 HMS 蛋白的小鼠减少得更多。组织病理学分析显示，与 HMS-明矾制剂相比，接受 HMS-MPL 的组的肾组织病理变化更多。用HMS-明矾和HMS-MPL制剂免疫的两组的存活率相等。最后，可以得出结论，明矾佐剂和 MPL 都是适合 HMS 候选疫苗的免疫应答增强剂。